
Oncology NEWS International
- Oncology NEWS International Vol 7 No 12
- Volume 7
- Issue 12
Full FDA Approval for Camptosar
ROCKVILLE, Md-The FDA has granted full approval to Pharmacia & Upjohn’s Camptosar (irinotecan), based on survival data. Camptosar is indicated for use in patients with metastatic colorectal cancer whose disease has recurred or spread after treatment with the current standard chemotherapy. The agent received accelerated FDA approval in June 1996.
ROCKVILLE, MdThe FDA has granted full approval to Pharmacia & Upjohns Camptosar (irinotecan), based on survival data. Camptosar is indicated for use in patients with metastatic colorectal cancer whose disease has recurred or spread after treatment with the current standard chemotherapy. The agent received accelerated FDA approval in June 1996.
Articles in this issue
about 27 years ago
Long-Term Adjuvant Tamoxifen Urged for Low-Risk Breast Cancerabout 27 years ago
EORTC DCIS Study Confirms Recurrence Reduction With RTabout 27 years ago
James Cancer Center Joins NCCN Outcomes Databaseabout 27 years ago
Managed Care Sees Need for National Guidelines, Accreditationabout 27 years ago
Advisory Panel Recommends Approval of Vysis HER2 Testabout 27 years ago
Drinking Tea After Smoking May Reduce Oxidative Stressabout 27 years ago
Use Special Skills, Tools to Assess Pain in Children, Elderlyabout 27 years ago
Good Response Rates With Radiolabeled Anti-CD20 MoAB in NHLabout 27 years ago
Tobacco Industry Settles With StatesNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.


















































































